Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about cost and coverage, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.
The condition it depends on
Coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.
What I am not sure about
What I am after is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
InsuranceTom said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:
- Prior authorization appeal with peer-to-peer review
- Manufacturer copay card (for commercial insurance)
- Patient assistance programs (Novo Nordisk, Eli Lilly)
- Compounded medication from a 503B pharmacy ($133/month)
- Canadian pharmacy (requires prescription, ~40-60% savings)
Don't let cost prevent access to effective treatment. There are options at every price point.
InsuranceTom said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsLarryQC_SD said:The affordability discussion here usually stops at individual tactics.
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $287/month (eating less)
- Restaurants: SAVED $177/month (fewer meals out)
- Alcohol: SAVED $127/month (stopped drinking)
- Life insurance: Premium REDUCED by $37/month (lower BMI)
- Copays: SAVED $77/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
Dr.GastroMayo said:Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…
Mine went the same way, slower.